The Role of Disease Modifying Therapy In The Treatment of Relapsing Remitting Multiple sclerosis

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorRawashdeh, Amir
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intenzív Terápiás Osztályhu_HU
dc.date.accessioned2019-01-30T12:22:09Z
dc.date.available2019-01-30T12:22:09Z
dc.date.created2018-09-03
dc.description.abstractAlthough there is no definitive cure for multiple sclerosis, immunomodulatory agents developing since the mid 1990’s have surfaced and produced beneficial effects in decreasing relapse rate and, some agents more than others, reducing disability progression. These group of drugs are termed “Disease modifying therapy” and it mostly benefit patients with a multiple sclerosis of a relapsing and remitting course. However, choosing an agent out of the big arsenal of disease modifying therapy is not always easy and in fact it poses a challenging prospect for the treating physician. The initial treatment agent should be chosen according to the patient’s preference, convenience and values, without a guarantee that this treatment will be tolerated by the patient.hu_HU
dc.description.correctorSZG
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent35hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/263428
dc.language.isoenhu_HU
dc.subjectdisease modifying thrapyhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológiahu_HU
dc.titleThe Role of Disease Modifying Therapy In The Treatment of Relapsing Remitting Multiple sclerosishu_HU
Fájlok